**New acyclic *bis* phenylpropanoid and neolignans, from *Myristica fragrans* Houtt.,
exhibiting PARP-1 and NF- κ B inhibitory effects.**

Ulyana Muñoz Acuña^{a,b}, Peter J. Blanco Carcache^a, Susan Matthew^a, and Esperanza J. Carcache de
Blanco^{a,b*}.

^aDivision of Pharmacy Practice and Administration and ^bDivision of Medicinal Chemistry and
Pharmacognosy, College of Pharmacy, The Ohio State University, 141N Parks Hall 500 W. 12th Avenue,
Columbus, OH 43210.

*Corresponding author. Fax.: +1-614-292-1335. E-mail address: carcache-de-blan.1@osu.edu

24 Abstract

25 The bioassay-guided fractionation of the aril of *M. fragrans* (mace spice) yielded five
26 phenolic compounds, one new acyclic *bis* phenylpropanoid (**1**) and four previously known
27 phenolic compounds: compounds (**1**) (*S*) 1-(3, 4, 5-trimethoxyphenyl)-2-(3-methoxy-5-(prop-1-
28 yl) phenyl)- propan-1-ol, (**2**) benzenemethanol; α -[1-[2,6-dimethoxy-4-(2-propen-1-
29 yl)phenoxy]ethyl]-3,4-dimethoxy-1-acetate, (**3**) odoratisol A, phenol, 4-[(2*S*, 3*S*)-2,3-dihydro-7-
30 methoxy-3-methyl-5-(1*E*)-1-propenyl-2-benzofuranyl]-2,6-dimethoxy, (**4**) 1,3-benzodioxate-5-
31 methanol, α -[1-[2,6-dimethoxy-4-(2-propenyl)phenoxy]ethyl]-acetate, (**5**) licarin C; benzofuran,
32 2,3-dihydro-7-methoxy-3-methyl-5-(1*E*)-1-yl-2-(3,4,5-trimethoxyphenyl). A NMR tube Mosher
33 ester reaction was used in an approach to characterize and determine the assignment of the
34 absolute configuration of the new isolated chiral alcohol (**1**). The PARP-1 inhibitory activity
35 was evaluated for compound (**1**) (IC_{50} = 3.04 μ M), compound (**2**) (IC_{50} = 0.001 μ M), compound
36 (**4**) (IC_{50} = 22.07 μ M) and compound (**5**) (IC_{50} = 3.11 μ M). Furthermore, the isolated secondary
37 metabolites were tested for NF- κ B and K-Ras inhibitory activities. When tested in the p65 assay,
38 compounds (**2**) and (**4**) displayed potent NF- κ B inhibition, (IC_{50} = 1.5 nM and 3.4 nM,
39 respectively).

40 Keywords: *Myristica fragrans*, mace, neolignans, acyclic bisphenyl propanoids, PARP-1, NF- κ B, K-Ras

1. Introduction

Nutmeg and mace from *Myristica fragrans* (Houtt) are both Old World spices. *M. fragrans* is a 9-12 m tall tree with small yellow flowers, native to the Banda Islands in the Maluku Province, Indonesia. This plant is a spice highly consumed by different cultures. The aril of *M. fragrans* (mace), used in this study, surrounds the seed (nutmeg), and is traditionally used for its culinary and medicinal properties.

Ethnobotanical research has shown that nutmeg and mace are used for stimulant and digestive purposes, and are used in local healing practices to treat certain ailments, such as rheumatism, nervousness, stomach and kidney disorders (Van Gils & Cox, 1994). In addition, *M. fragrans* is used in traditional Tibetan and Chinese medicine (Duan, Tao, Hao, Gu, & Zhu, 2009). In Ayurvedic medicine, mace is used to treat low fever, asthma, and to alleviate gastrointestinal complaints (Hattori, et al., 1988). Various biological activities have previously been reported for *M. fragrans*, such as analgesic, anti-inflammatory (Mueller, Hobiger, & Jungbauer, 2010), antioxidative (Surveswaran, Cai, Corke, & Sun, 2007), antitumor, and antibacterial properties. The uses of *M. fragrans*, both as a remedy and as a spice, suggest that the active constituents may display potential in prevention and/or treatment of different ailments. Essential oil, fatty acids, glycerides, cyclic, and acyclic *bis*-phenylpropanoids have previously been identified in *M. fragrans* (Hattori, et al., 1988). Acyclic bisphenyl propanoids are phenolic secondary metabolites reported only to be found in plants belonging to the Myristicaceae family (Hada, Hattori, Tezuka, Kikuchi, & Namba, 1988).

There is increasing evidence to show that a diet rich in phenolic constituents from food-related plants may have health-beneficial effects (Scalbert, Manach, Morand, Rémésy, & Jiménez, 2005), and may protect against the development of chronic inflammatory diseases

(Janega, et al., 2014; Zamora-Ros, et al., 2014). Epidemiological studies suggest that compounds found in food-related plants might protect against various types of cancers, such as lung, colon, prostate, and breast malignancies (Feskanich, et al., 2000; Sun, Yuan, Koh, & Yu, 2006; Tang, Zhou, Wang, Yu, & Ma, 2009; Yan & Spitznagel, 2009). Furthermore, this is supported by studies showing that phytochemical constituents may have potential anticancer activities, e.g.; epigallocatechin-3-gallate found in tea (Chung, Huang, Meng, Dong, & Yang, 1999), genistein from soy (Gong, Li, Nedeljkovic-Kurepa, & Sarkar, 2003), capsaicin found in pepper (Han, Keum, Chun, & Surh, 2002), sulforaphane present in cruciferous vegetables (Dinkova-Kostova, et al., 2002) and curcumin, found in the Indian spice, turmeric (Singh & Aggarwal, 1995).

A study on effects of a phytochemical on regulatory elements involved in transcription and phenotype maintenance, may aid in understanding the mechanism involved in chemoprevention by phytochemicals present in the diet. It has been previously reported that PARP-1 coactivates NF- κ B p65 (RelA) during transcription (Hassa, et al., 2005). Inhibitors for these two factors, if found, may be tested for prevention of malignant tumor formation.

The potential health benefits of secondary metabolites found in food-related plants gives scope for identification of a biological target to confer a protective effect against chronic inflammatory conditions. In the present study, isolation of phytochemical constituents from mace (through ethyl acetate partitioning) and an assessment of their effects on PARP-1, NF- κ B and K-RAs is reported. The structure-activity relationship of the bioactive constituents is discussed in some detail.

2. Materials and methods

2.1. General

¹H, ¹³C, DEPT, HSQC, and HMBC NMR spectra were measured, using a Bruker Avance 400 MHz spectrometer. The ¹H-NMR spectra were recorded at 400 MHz, using chloroform-*d* (CDCl₃) and pyridine-*d*₅ solutions (Cambridge Isotope Laboratories, MA, USA). Tetramethylsilane (TMS) was used as an internal standard. Molecular weights were obtained, using a Waters Q-ToF micro mass spectrometer and a Bruker maXis Q-ToF mass spectrometer.

Open column chromatography was performed, using silica gel 60 GF₂₅₄ (70-230 mesh), Whatman, (GE Healthcare, Piscataway, NJ). Methanol and acetonitrile (Fisher Scientific Fair Lawn, NJ) were used for extraction and isolation. Thin-layer chromatography (TLC) plates F₂₅₄ (Merck, Darmstadt, Germany) were used to monitor the separation. The TLC plates were developed by using a solution of 10% H₂SO₄ in ethanol with 1% vanillin and heated to visualize the separation. Preparative and analytical HPLC were carried out, using a Waters 600 controller equipped with a 996 photodiode array detector and a Waters SunFire RP₁₈ column (21.2.x 250 mm, 10 μm) from Waters (Millford, MA). The isolation was pursued using a ternary solvent system composed of an aqueous phase **A** (mixture of acetic acid in water (0.025%)) and an organic phase **B**, composed of methanol and acetonitrile. The optical rotation was obtained in a Perkin Elmer model 345 polarimeter at 20 °C, using a sodium lamp (589 nm). The circular dichroism (CD) measurements were performed using a Jasco Model J-810 spectropolarimeter. The absorbance was measured by using a microplate reader FLUOstar Optima fluorescence plate reader (BMG Labtechnologies GmbH, Inc, Durham, NC, USA). The isolated compounds were characterized and identified by comparing their physical properties and spectroscopic data with literature reports (UV, MS, ¹H- and ¹³C NMR). The carbon assignment for similar compounds has previously been reported (Hattori, et al., 1988).

Compound **2**, benzenemethanol, α -[(1, *R*)-1-[2,6-dimethoxy-4-(2-propen-1-yl)phenoxy]ethyl]-3,4-dimethoxy-1-acetate (**2**), has previously been reported and described (Duan, Tao, Hao, Gu, & Zhu, 2009).

Compound **3**, odoratisol A, phenol, 4-[(2*S*, 3*S*)-2, 3-dihydro-7-methoxy-3-methyl-5-(1*E*)-1-propenyl-2-benzofuranyl]-2,6-dimethoxy (**3**), has previously been reported and described (Giang, Son, Matsunami, & Otsuka, 2006).

Compound **4**, 1,3-benzodioxole-5-methanol, α -[1-[2,6-dimethoxy-4-(2-propenyl)phenoxy]ethyl]-acetate (**4**) also has previously been isolated, identified, and reported (Forrest, Heacock, & Forrest, 1974; Zacchino & Badano, 1991).

Compound **5**, licarin C, benzofuran, 2,3-dihydro-7-methoxy-3-methyl-5-(1*E*)-1-yl-2-(3, 4, 5-trimethoxyphenyl) (**5**) has previously been isolated and described (Braz Filho, Mourao, Gottlieb, & Maia, 1976; Wenkert, Gottlieb, Gottlieb, Pereira, & Formiga, 1976).

2.2. Plant material

The dry aril of *Myristica fragrans* (mace) was purchased at a local Indian grocery market. A voucher specimen was deposited in the research laboratory.

2.3. Extraction, isolation and identification

2.3.1. General

The dry aril of *M. fragrans* (1.2 kg) was macerated and extracted, using 3 x 2000 ml of methanol to obtain the crude extract. The extract was filtered and dried under vacuum to yield the crude extract. The extract was dissolved in water and sequentially partitioned, using chloroform, ethyl acetate, and butanol (3 x 300 ml). The ethyl acetate layer displayed significant

activity in the PARP-1 assay (74% inhibition at 50 mg/ml) and in the NF- κ B p65 inhibitory assay and thus was submitted to bioassay-guided isolation. The fractionation was performed over an open column, employing silica gel 60 GF₂₅₄ (70-230 mesh, Merck) as the stationary phase. The sample was eluted with a gradient composed of a solvent mixture of water: methanol (50→0). The sample was eluted in gradient steps of 100 ml. Each fraction was collected in volumes of 20 ml. During isolation, the separation was monitored, using thin-layer chromatography (TLC). The aluminium plates were pre-coated with silica gel 60 F₂₅₄. A mixture composed of water and acetonitrile (5:95) was used for separation. The constituents were visualized by spraying with a 10% solution of sulfuric acid and 1% vanillin in ethanol, followed by heating the plates. The fractions were combined according to the results of the TLC analysis. Ten fractions were obtained from this separation (1-10). Analysis of TLC fractions was carried out using reverse-phase HPLC, with a solvent system composed of acetic acid in water (0.025%) (**A**), and a mixture of methanol and acetonitrile (**B**), with a gradient of 95:5→0:100, run over 45 minutes. The column was washed by using 100% of organic solvent for 10 minutes, before going back to initial conditions (95:5). The separation was monitored at $\lambda=224$ nm.

The active fraction was re-chromatographed. Further purification of the active mixture was achieved on a preparative HPLC system with a Waters[®] SunFire column (10 x 150 mm, 10 μ m), using a ternary solvent system composed of acetic acid in water (0.025%) as eluent mixture **A** and a mixture of methanol and acetonitrile (1:1) as eluent mixture **B**. The peaks were chromatographically separated under isocratic conditions (30:70 of solvents **A** and **B**) for a duration of 45 minutes. Each run was followed by washing the column with 100% of solvent **B**, before restoring initial conditions (30:70). The flow-rate during the chromatographic separation was 5 ml/min. Eight peaks were collected at the following time-points; $t_R = 10$ min (2.6 mg), $t_R =$

15 min (6.0 mg), t_R = 19 min (22.5 mg) t_R 21= min (11.9 mg), t_R = 22 min (14.7 mg) and t_R = 24 min (22.2 mg), t_R = 28 min (4.2 mg) and t_R = 40 min (7.8 mg), respectively. Five neolignans were obtained and characterized from this separation (Fig. 1). Compound **1** (22.2 mg) had a retention time of t_R = 24 min, compound **2** (22.5 mg) had a t_R = 19 min, compound **3** (14.7 mg) had a retention time t_R = 22 min, compound **4** (4.2 mg) had a t_R = 28 min, and compound **5** (7.8 mg) had a t_R = 40 min. The identification was achieved by MS and NMR analysis, and by comparing the obtained spectroscopic data of each compound with previous literature on *M. fragrans* (Hattori, *et al.*, 1988). The ^1H and ^{13}C NMR spectra were determined and the optical rotation was obtained.

To determine the absolute configuration at C-1 in compound **1** (Fig. 2.), preparation of both the (*R*) and (*S*)-MTPA ester derivatives of **1** was pursued following the previously described modified Mosher method (Su, *et al.*, 2002). The amount of 0.5 mg of compound **1** was transferred, using deuterated pyridine- d_5 (0.6 ml), to a NMR tube. The chiral substrate was dispensed into the corresponding NMR tube under addition of argon gas. (*S*)- (+)- α -Methoxy- α -(trifluoromethyl)phenylacetyl chloride (MTPA Cl) (6 μl) was used as a substrate to obtain the (*R*)-MTPA ester derivative, and (*R*)-(+)- α -methoxy- α -(trifluoromethyl)phenylacetyl chloride was used to obtain the (*S*)-MTPA ester derivative. Subsequently, the sample mixtures were covered and evenly shaken, the mixtures were allowed to react for 6 h. The chiral substrate MTPA-chloride was coupled to the chiral secondary alcohol to obtain the two configurations. The obtained (*R*)- and (*S*)-MTPA Cl ester derivatives were analyzed by ^1H -NMR.

2.3.2. (*S*) 1-(3,4,5-Trimethoxy phenyl)-2-(3-methoxy-5-(prop-1-yl) phenyl)-propan-1-ol (**1**)

Compound **1** was obtained as a yellow oil; UV (methanol) λ_{max} (log ϵ) 210 (3.89), 268 nm (4.00): $[\alpha]_{\text{D}}^{20} +18$ (c 1.0, MeOH). CD (MeOH) λ_{max} ($\Delta\epsilon$) 245 (-3.67116), 270 (6.65641). The molecular mass was determined (m/z 395.14). The molecular formula was determined to be $\text{C}_{22}\text{H}_{28}\text{O}_5$ on the basis of the positive HRESIMS: m/z 395.1620 $[\text{M}+\text{Na}]^+$. The formula requires 7° of unsaturation. For ^1H NMR and ^{13}C NMR resonances see Table 1.

2.4. PARP-1 inhibitory assay

Poly (adenosine 5'-diphosphate (ADP)-ribose) polymerase 1(PARP-1) is a nuclear chromatin enzyme involved in single strand DNA breaks (SSB). PARP-1 is activated by DNA damage. The small molecules that inhibit the PARP-1 enzyme lead to accumulation of DNA damage, and potentiate anticancer activities by increasing the sensitivity of cancer cells to cytotoxic agents and instigating apoptosis. (Muñoz-Gámez, et al., 2005) The isolated secondary metabolites (**1-5**) from *M. fragrans* were tested by using the PARP-1 Chemoluminescent Activity Assay Kit (BPS Bioscience). First, the 96-well plate was coated with histones, by adding 50 μl of prepared histone solution to each well and allowed to incubate at 4°C overnight. The plates were washed three times with ice-cold PBS-Tween (200 μl), before adding blocking buffer to each well. The plates were washed three times with ice-cold PBS-Tween. A reaction mixture, containing activated DNA, PARP-1 buffer, and assay buffer, was added to each well. The plates were washed three times with ice-cold PBS-Tween. The samples tested were diluted in dimethylsulfoxide (10%) and added to the corresponding wells before the addition of PARP-1. The plate was covered and incubated at 20°C for 1 h. The plate was washed three times, before streptavidin-HRP was added to each well, and allowed to incubate at 20°C for 30 min. The chemiluminescent solution was added to each well and luminescence was detected and measured at 410 nm, using a Fluostar Optima plate reader (BMG Labtech Inc).

2.5. *NF- κ B* inhibitory assay

The HeLa human cervical cancer cell line was purchased from American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and with 100 IU/ml of penicillin and streptomycin from Gibco (Rockville, MD, USA). The cells were cultured in 75 ml tissue flasks at a temperature of 37°C in an atmosphere containing 5% CO₂. The NF- κ B assay was carried out according to previously established protocol (Kim, Lau, Pan, & Carcache De Blanco, 2010). Briefly, a nuclear extract was prepared from the treated and untreated HeLa cells. The analysis of the effects on the NF- κ B inflammatory pathway was studied, using a specific ELISA binding assay with a luminescent detection system. The inhibitory effect on transcription factor NF- κ B p65 was evaluated in HeLa cells, using the Transcription Assay System (Pierce Biotechnology, Rockford, IL). This allowed the assessment of the binding affinity of the NF- κ B subunit p65 to its corresponding biotinylated consensus sequence. The luminescence readings detected in the treated samples were compared to the negative control, treated with tumor necrosis factor- α (TNF α) (Thermo Scientific, Rockford, IL, USA). The inhibitory concentration (IC₅₀) was calculated for the tested compounds and compared to the positive control rocaglamide (IC₅₀ = 0.08 μ M) (Enzo Life Sciences, Inc. Farmingdale, NY, USA). Luminescence was detected by using a FLUOstar Optima plate reader (BMG Labtech Inc, Durham, NC). The obtained data were analyzed using Table Curve 2D v4.

2.6. *K-Ras* inhibitory assay

The assay was performed by following a previously published protocol (Muñoz Acuña, Matthew, Pan, Kinghorn, Swanson & Carcache de Blanco, 2013). The human colorectal HT-29

cell line was purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) and was cultured in Roswell Park Memorial Institute Media (RPMI-1640) supplemented with 100 IU/ml of penicillin and streptomycin from Gibco (Rockville, MD, USA). The cells were treated and incubated at a temperature of 37°C, in an atmosphere containing 5% CO₂, for 3h. This was followed by the removal of the medium and they were then washed three times with phosphate-buffered saline (PBS) and treated with EGF solution (5 ng/ml) for 2 min. Protease inhibitor was added and the cells were then lysed. The aliquots were stored at a temperature of -80 °C. The protein concentration was determined in each sample, before the K-Ras activity was assessed, by using the Ras GTPase Chemi Elisa kit from Activity Motif (Carlsbad). The primary K-Ras antibody (1:5000) was added to each well and incubated at room temperature for 1h. Subsequently, the HRP- conjugated secondary antibody was used for detection. Chemiluminescence solution was added, and the luminescence was read, using a Fluostar Optima plate reader (BMG Labtech Inc).

2.7. SRB Cytotoxicity assay

The anti-proliferative effects of the isolated neolignans from mace were tested on the human colorectal HT-29 cell line, using a previously published protocol (Muñoz Acuña, Nighat, Ahmed, Chang, & Carcache de Blanco, 2013). The cells were cultured in RPMI-1640 media supplemented with 10% fetal bovine serum (FBS) and 100 IU/ml of penicillin and streptomycin, both from Gibco (Rockville, MD, USA). The cells were grown in T75 tissue culture flasks as a monolayer at a temperature of 37°C and in 5% CO₂. The compounds were diluted in 10 % dimethylsulfoxide and the cells were subsequently treated in a concentration range (0.25 ng/ml-

25 µg/ml). The cell suspension was seeded in a 96-well plate (1×10^5 cells per well) and treated with serial dilutions of the isolated compounds (**1-5**) and incubated for 72 h at a temperature of 37°C and in an atmosphere of 5% CO₂. The cells were fixed, using 100 µl of ice-cold trichloroacetic acid (20%) for 30 min at a temperature of 4°C. The cells were then stained by adding 100 µl of sulforhodamine (SRB) (0.4%) and kept at a temperature of 20 °C for 30 min, before washing the wells three times with acetic acid (1%) and then letting them air-dry. The stained cells with the bound dye were solubilized by adding 200 µl of Tris base solution (10 mM) to each well. Then, the 96-well plate was placed on a shaker for 5 min. The absorbance reading was performed at a wavelength of 515 nm, using the FLUOstar Optima plate reader (BMG Labtech Inc, Durham, NC). The absorbance values were compared to the untreated control samples and effective concentration (EC₅₀) was calculated, using Table Curve 2Dv4 (System Software Inc., San Jose, CA, USA). Paclitaxel was used as a positive control. The assay was run in triplicate.

2.8. Statistical analysis

Experimental results are presented as means $\pm$ SEM and all measurements and analyses were carried out in triplicate. Excel and TableCurve 2D 4v were used for statistical and graphical evaluations in this study.

3. Results and discussion

3.1. Isolation and structure elucidation

Briefly, a new acyclic *bis* phenylpropanoid was isolated from mace, using a preparative HPLC system with a trinary eluent solvent system composed of a mixture of acetic acid

(0.0025%), methanol and acetonitrile. Compound **1** was isolated as yellow oil and identified using NMR spectrometric methods. The HRESIMS data, giving m/z 395.1620 $[M+Na]^+$, established the molecular formula as $C_{22}H_{28}O_5$. The 1H NMR spectrum exhibited two methyl group signals at δ_H 1.41 ppm (3H, $J=6.7$ Hz) and δ_H 1.89 ppm (3H, d $J=6.5, 1.9$ Hz), respectively. The integration of the signals at δ_H 3.90 ppm (3H, s) allowed the identification of four methoxy groups. A methine group was detected at δ_H 3.50 ppm (1H, s), and the spectrum showed a signal of an oxygenated methine at δ_H 5.10 ppm (1H, d, $J=9.6$). The vinylic protons displayed signals at δ_H 6.10 ppm (1H, dd $J=6.5, 16$ Hz) and at δ_H 6.40 ppm (1H, dd $J=16, 1.9$ Hz). Three aromatic signals were found at δ_H 6.46 ppm (1H, s), δ_H 6.77 ppm (1H, s) and 6.82 ppm (1H, m) (1H, s). The integration of signals at δ_H 6.98 ppm (2H, s) allowed the identification of two aromatic protons.

In the ^{13}C spectrum, the carbon signals at δ_c 132.6 (C-1''), 109.3 (C-2'') (C-6''), 146.3 (C-3'') (C-5'') 150.9 ppm (C-5'') indicated the presence of a 1, 2, 3-trimethoxy-5-methylbenzene moiety. The carbon shifts at δ_c at 133.7 (C-1'), 113.8 (C-2'), 131.2 (C-3'), 114.6 (C-4'), 144.6 (C-5'), 106.1 (C-6'), and 131.4 (C- α), 123.6 (C- β), and δ_c 19.0 ppm (C- γ) suggested the presence of a 1-methoxy -3-methyl-5(prop-1-en-yl)benzene moiety in the structure. This was confirmed by the long-range correlations in the HMBC experiment, where the proton at δ_H 6.46 ppm showed correlation to carbon at δ_c 113.8 (C-2') and 133.7 ppm (C-1'). Similarly, this was confirmed by the long-range heterocoupling signals in the HMBC spectrum. The proton at δ_H 6.82 ppm (H-4') showed correlation to carbons at δ_c 133.7 (C-1'), 144.6 (C-5'), and 106.1 (C-6') ppm. The proton at δ_H 6.77 ppm showed correlation to carbons at δ_c 133.7 (C-1'), 47.0 (C-2) and 113.8 (C-2') ppm. The protons at δ_H 1.90 ppm (H- γ) showed long range correlations to carbons at δ_c 123.6 (C- β) and 131.3 ppm (C- α). Carbon signals of a methyl group with carbon shifts δ_c at

18.2 ppm (C-3) were detected upfield in the carbon spectrum; a methine at δ_c 47.0 ppm (C-2) and an oxymethine at δ_c 94.4 ppm (C-1) were also displayed in the spectrum.

The long range correlations (HMBC) were between protons at δ_H 1.40 ppm (H-3) of the methyl group and carbon at δ_c 94 ppm (C-1), δ_c 47.0 ppm (C-2) and with carbon at δ_c 133.7 ppm (C-1'). The proton at δ_H 3.90 ppm (O-CH₃) showed correlation to carbon δ_c 146.3 (C-3'') (C-5'') and 150.9 ppm (C-4''). The proton at δ_H 3.50 ppm (H-2) showed HMBC correlations to carbons at δ_c 94.4 ppm (C-1), 47.0 ppm (C-2) and 132.6 (C-1'') ppm. The proton at δ_H 5.10 ppm (H-1) showed correlations to carbons at δ_c 94.4 (C-1), 47.0 (C-2), 18.2 (C-3), 132.6 (C-1'') and 113.8 (C-2'') ppm. Thus, the complete assignment of the acyclic *bis*-phenylpropanoid structure of (**1**) was achieved through the HMBC experiment.

The COSY experiment confirmed the assigned structure and showed 2D correlation between protons at δ_H 3.50 (H-2) and 5.10 ppm (H-1), and correlations between δ_H 6.10 ppm (H- β) and δ_H 6.40 ppm (H- α). Moreover, the NOESY experiment showed correlation between the vicinal protons at 3.50 (H-2), 5.10 (H-1), and 6.98 (H-2'') ppm.

Compound **1** was identified upon comparison with a similarly assigned structure (Wenkert, et al 1976).

The absolute configuration determines the biological and pharmacological activity; thus, it is of great significance to characterize this property on bioactive molecules. The presence of the secondary hydroxyl group on C-1 was used to empirically determine the absolute configuration by employing two chiral substrates, (*S*)- and (*R*)-MTPA-chloride, to create the two Mosher ester derivatives with two different stereocentres. The procedure describing the configuration of the stereocentre of a secondary alcohol was previously described (Su, et al.,

2002). The stereochemical assignment was based on comparison of the two ^1H -NMR spectra. This comparison allowed the assessment of the diamagnetic effect of the α -phenyl group present in the MTPA chloride moiety on the selected proton shifts of H-3. When comparing the two pairs of signals for H-3, the two isomers were distinguishable by the difference in chemical shift δ -values ($\Delta\delta^{\text{S-R}}$). The ^1H -NMR spectra were assessed for each one of the enantiomers, **1s** and **1r** and the difference between the two signals for H-3 of the two chiral residues showed a negative $\Delta\delta^{\text{SR}}$ value of -0.002 ppm (Fig. 3) (Ren, et al., 2012). The shielded protons displayed negative $\Delta\delta^{\text{SR}}$ values (Su, et al., 2002) and compound (**1**) was assigned as (*S*) 1-(3, 4, 5-trimethoxy phenyl)-2-(3-methoxy-5-(prop -1-yl) phenyl)-propan-1-ol.

Compound **2** was isolated as yellow oil. The obtained chemical formula was $\text{C}_{24}\text{H}_{30}\text{O}_7$, calculated for m/z $[\text{M}+\text{Na}]^+$ 453.11. The ^1H , ^{13}C , DEPT, HSQC, and HMBC experiments were used for structural assignment and identification. Based on comparison with literature data, compound (**2**) was identified as benzenemethanol, α -[(1, *R*)-1-[2,6-dimethoxy-4-(2-propen-1-yl)phenoxy]ethyl]-3,4-dimethoxy-,1-acetate (Duan, et al., 2009).

Compound **3** was isolated as yellow oil. The m/z 379.12 $[\text{M}+\text{Na}]^+$ corresponded to a chemical formula of $\text{C}_{21}\text{H}_{24}\text{O}_5$. The proton spectrum was compared to previously published data and led to the identification of phenol, 4-[(2*S*, 3*S*)-2, 3-dihydro-7-methoxy-3-methyl-5-(1*E*)-1-propenyl-2-benzofuranyl]-2,6-dimethoxy (odoratisol A) (Giang, et al., 2006)

Compound **4** was isolated as yellow oil. With a m/z of 437.12 $[\text{M}+\text{Na}]^+$. The chemical formula corresponded to $\text{C}_{23}\text{H}_{26}\text{O}_7$. The ^1H , ^{13}C , DEPT, HSQC and HMBC experiments were used for structural assignment and identification. Based on comparison with literature data,

compound (**3**) was identified as 1,3-benzodioxole-5-methanol, α -[1-[2,6-dimethoxy-4-(2-propenyl)phenoxy]ethyl]-acetate (Forrest, et al., 1974) (Zacchino & Badano, 1991).

Compound **5** was isolated as yellow oil. The elemental formula $C_{22}H_{26}O_5$ was calculated for m/z $[M+Na]^+$ 393.16. The 1H , ^{13}C , DEPT, HSQC and HMBC experiments were used for structural assignment and identification. Based on comparison with literature data, compound (**4**) was identified as benzofuran, 2, 3-dihydro-7-methoxy-3-methyl-5-(1*E*)-1-yl-2-(3, 4, 5-trimethoxyphenyl) (Aiba, et al., 1977; Kapooret, et al., 2013; Wenkert, et al., 1976).

3.2. PARP-1 inhibition in vitro

The poly (adenosine 5'-diphosphate (ADP)-ribose) polymerase (PARP-1) is a nuclear chromatin-bound enzyme involved in single strand DNA breaks (SSB). PARP-1 is activated by DNA damage. The small molecules that inhibit the PARP-1 enzyme potentiate anticancer activities by increasing the sensitivity of cancer cells to cytotoxic agents.

The EtOAc layer of *M. fragrans* displayed 78% inhibition when tested in a PARP-1 enzyme assay. The fractionation of the EtOAc layer yielded a fraction with enriched PARP-1 inhibitory activity (82% at 50 μ g/ml). Further, bioassay-guided isolation led to five secondary metabolites from *M. fragrans* (**1-5**). Although the four isolated compounds displayed inhibitory activity, compound (**2**) showed the highest PARP-1 inhibitory activity when tested by the enzyme PARP-1 inhibitory assay. PARP-1 activity was displayed by compound (**1**) (IC_{50} = 3.04 μ M), compound (**2**) (IC_{50} = 0.001 μ M), compound (**3**) (IC_{50} = 22.1 μ M) and compound (**4**) (IC_{50} = 3.11 μ M).

PARP-1 inhibitory activity has an anti-proliferative effect in malignant cancer cells. It has been shown that PARP-1 inhibition targets, particularly, breast and ovarian cancers with lack

of functioning repair proteins BRCA 1 and BRCA 2. PARP-1 inhibitors have been shown to be clinically effective for treatment of hereditary triple negative breast tumors that display loss of function of BRCA 1 and BRCA 2 mutations. Since the active compound originated from a diet-based product (mace), it might be possible to develop this compound as part of a dietary supplement formulation.

3.3. *NF- κ B p65 inhibitory assay in vitro*

The bioassay-guided fractionation of mace led to the isolation of five neolignans (**1-5**) that were tested for NF- κ B activity. The EtOAc layer displayed 39% inhibition in the NF- κ B p65 inhibitory assay. Both compound (**2**) and compound (**4**) showed potent NF- κ B inhibitory activity when tested in HeLa cells (Table 2). Compounds (**2**) and (**4**) displayed NF- κ B inhibitory concentrations of $IC_{50} = 1.5$ nM and $IC_{50} = 3.4$ nM, respectively. The inhibitory effect was compared to rocaglamide ($IC_{50} = 75$ nM). The transcription factor NF- κ B is associated with inflammation and cancer progression, and the results suggested that these neolignans might target inflammatory responses, particularly in malignant cells.

The transcription factor NF- κ B promotes survival signalling and triggers the resistance of cancer cells to certain tumorigenic agents and chemotherapy (Lerebours, et al.,) . The NF- κ B is a heterodimer composed by p65 bound to I κ B. The I κ B kinase (IKK) is responsible for phosphorylation of I κ B. The release from I κ B in the cytosol, activates NF- κ B before it is translocated to the nucleus (Perkins, 2007). The NF- κ B pathway is induced by cytokinin TNF- α (Yin, Chen, & Shu, 2009). This regulatory element exerts its anti-apoptotic effects in malignant cancer cells and it is hypothesized that targeting this regulatory element may sensitize tumor

cells to undergo programmed cell death. Thus, NF- κ B inhibition triggers apoptosis in cancer cells and induces apoptosis selectively in cancer cells (Darnell, 2002).

The aril of *M. fragrans* (mace) is a rich source of bio-active neolignans. While compound **(1)** showed no NF- κ B inhibitory activity, suggesting that the hydroxyl substitution in position C-1 interfere with the structure-activity of neolignans (Lin, et al., 1988), the activity of the two esters **(2)** and **(4)** suggested that the acetate function may have an essential role in mediating NF- κ B inhibition. Also, the presence of four methoxy-substituted groups in both aromatic rings seems to be involved in mediating NF- κ B inhibition. Thus, this study and the chemical characterization of neolignans may lead to the optimization of potent NF- κ B inhibitors in the near future.

3.4. In vitro K-Ras inhibitory activity

The K-Ras activity was assessed in HT-29 colon cancer cells treated with compounds **1-4**. The inhibitory concentration for compound **1** was $IC_{50} = 10.5 \mu M$. The results indicated that the hydroxyl group may be pivotal in mediating K-Ras inhibition; however, structural modifications may lead to optimization of K-RAs inhibitory activity. Since only compound **1** displayed activity of the neolignans in this study, it is suggested that K-Ras inhibition is mediated by a different mechanism of action. The growth factor EGF was used to stimulate the K-Ras pathway. The growth factor EGF is the ligand of the cell membrane-bound receptor EGFR, and induces the intracellular K-Ras protein downstream. The oncogenic K-Ras mutations are commonly found in colon cancers (Nandan, et al., 2008; Telang, Lane, Nelson, Arumugam, & Chesney, 2007). According to previous studies, K-Ras may provide a possible target to prevent the progression of colon cancer (Karapetis, et al., 2008).

3.5. Cytotoxicity in vitro

It has previously been shown that naturally occurring phenyl propanoids are cytotoxic against leukemia (Liu et al., 2006). In this study, we tested the cytotoxicity of the compounds isolated from the aril of *M. fragrans* in HT-29 human colon cancer cell lines (Table 2). Three of the four compounds showed activity when tested in the SRB-assay. Compound **2** ($EC_{50} = 3.07 \mu M$), compound **4** ($EC_{50} = 0.024 \mu M$) and compound **5** ($EC_{50} = 0.003 \mu M$) showed cytotoxicity in the SRB assay when tested against HT-29 colon cancer cell lines. Compound **3** showed moderate cytotoxicity and compound **4** displayed the highest cytotoxicity in HT-29 cells, when the activity was compared to the positive control paclitaxel ($EC_{50} = 0.0005 \mu M$). This is supported by previous studies that have shown that neolignans exhibit antiproliferative activities against HT-29 colon cancer cells (Kong, Tzeng, & Liu, 2005).

4. Conclusion

The phytochemical investigation of mace afforded five compounds (**1-5**). The neolignans isolated from mace displayed inhibitory effects on mediators in the inflammatory pathway and, furthermore, showed antiproliferative effects. Bioassay-directed fractionation led to the identification of PARP-1 inhibitory secondary metabolites and NF- κ B inhibitors. These findings suggested that neolignans present in food-plants may have health- beneficial effects, possibly in the management of disease states associated with inflammatory conditions. The results of this study warrant future chemopreventive studies, since the secondary metabolites in mace display antineoplastic effects and inhibit regulatory elements involved in DNA maintenance. In

summary, the aril of *M. fragrans* is a sustainable source of neolignans and it comprises a promising source of new phytonutrients with potential great health-beneficial effects.

Acknowledgements

We would like to thank Dr. Craig McElroy for facilitating the use of NMR instrumentation. The authors are also thankful to Dr. Li Pan for kind guidance and assistance with instrumentation. The authors would like to acknowledge Mr. Mark Apsega and Andrew VanSchoiack for assisting with mass spectrometry (NSF award 1040302) as a purchase service. This work was partially supported by the Diversity Supplement P01 CA125066-S2, funded by the National Cancer Institute, NIH, Bethesda, MD.

References

- Braz Filho, R., Mourao, J. C., Gottlieb, O. R., & Maia, J. G. S. (1976). Lanthanide induced shifts as an aid in the structural determination of eusiderins. *Tetrahedron Letters*, 15, 1157-1160.
- Chung, J. Y., Huang, C., Meng, X., Dong, Z., & Yang, C. S. (1999). Inhibition of activator protein 1 activity and cell growth by purified green tea and black tea polyphenols in H-ras-transformed cells: structure-activity relationship and mechanisms involved. *Cancer Research*, 59, 4610-4617.
- Darnell, J. E., Jr. (2002). Transcription factors as targets for cancer therapy. *Nature Reviews Cancer*, 2, 740-749.
- Dinkova-Kostova, A. T., Holtzclaw, W. D., Cole, R. N., Itoh, K., Wakabayashi, N., Katoh, Y., Yamamoto, M., & Talalay, P. (2002). Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. *Proceedings of National Academy of Sciences U S A*, 99, 11908-11913.

439 Duan, L., Tao, H. W., Hao, X. J., Gu, Q. Q., & Zhu, W. M. (2009). Cytotoxic and antioxidative phenolic
440 compounds from the traditional Chinese medicinal plant, *Myristica fragrans*. *Planta Medica*, 75,
441 1241-1245.

442 Feskanich, D., Ziegler, R. G., Michaud, D. S., Giovannucci, E. L., Speizer, F. E., Willett, W. C., &
443 Colditz, G. A. (2000). Prospective study of fruit and vegetable consumption and risk of lung
444 cancer among men and women. *Journal of National Cancer Institute*, 92, 1812-1823.

445 Forrest, J. E., Heacock, R. A., & Forrest, T. P. (1974). Diarylpropanoids from nutmeg and mace
446 (*Myristica fragrans* Houtt.). *Journal of the Chemical Society, Perkins Transaction 1 Soc Perkin*
447 *1*, 2, 205-209.

448 Giang, P. M., Son, P. T., Matsunami, K., & Otsuka, H. (2006). New neolignans and lignans from
449 vietnamese medicinal plant *Machilus odoratissima* Nees. *Chemical Pharmaceutical Bulletin*, 54,
450 380-383.

451 Gong, L., Li, Y., Nedeljkovic-Kurepa, A., & Sarkar, F. H. (2003). Inactivation of NF-kappaB by
452 genistein is mediated via Akt signaling pathway in breast cancer cells. *Oncogene*, 22, 4702-4709.

453 Hada, S., Hattori, M., Tezuka, Y., Kikuchi, T., & Namba, T. (1988). Constituents of mace. Part 3. New
454 neolignans and lignans from the aril of *Myristica fragrans*. *Phytochemistry*, 27, 563-568.

455 Han, S. S., Keum, Y. S., Chun, K. S., & Surh, Y. J. (2002). Suppression of phorbol ester-induced NF-
456 kappaB activation by capsaicin in cultured human promyelocytic leukemia cells. *Archives of*
457 *Pharmaceutical Research*, 25, 475-479.

458 Hassa, P. O., Haenni, S. S., Buerki, C., Meier, N. I., Lane, W. S., Owen, H., Gersbach, M., Imhof, R., &
459 Hottiger, M. O. (2005). Acetylation of poly(ADP-ribose) polymerase-1 by p300/CREB-binding
460 protein regulates coactivation of NF-kappaB-dependent transcription. *Journal of Biological*
461 *Chemistry*, 280, 40450-40464.

462 Hattori, M., Yang, X. W., Shu, Y. Z., Kakiuchi, N., Tezuka, Y., Kikuchi, T., & Namba, T. (1988).
463 Constituents of mace. Part IV. New constituents of the aril of *Myristica fragrans*. *Chemical and*
464 *Pharmaceutical Bulletin*, 36(2), 648-653.

465 Janega, P., Klimentová, J., Barta, A., Kováčsová, M., Vranková, S., Cebová, M., Čierna, Z., Matúšková,
466 Z., Jakovljevic, V., & Pechánová, O. (2014). Red wine extract decreases pro-inflammatory
467 markers, nuclear factor- κ B and inducible NOS, in experimental metabolic syndrome. *Food*
468 *Functional*, 5, 2202-2207.

469 Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R.
470 J., Chalchal, H., Shapiro, J. D., Robitaille, S., Price, T. J., Shepherd, L., Au, H. J., Langer, C.,
471 Moore, M. J., & Zalcberg, J. R. (2008). K-ras mutations and benefit from cetuximab in advanced
472 colorectal cancer. *The New England Journal*, 359, 1757-1765.

473 Kim, J. A., Lau, E. K., Pan, L., & De Blanco, E. J. (2010). NF-kappaB inhibitors from *Brucea javanica*
474 exhibiting intracellular effects on reactive oxygen species. *Anticancer Research*, 30, 3295-3300

475 Kong, Z. L., Tzeng, S. C., & Liu, Y. C. (2005). Cytotoxic neolignans: an SAR study. *Bioorganic and*
476 *Medicinal Chemistry Letters*, 15, 163-166.

477 Lerebours, F., Vacher, S., Andrieu, C., Espie, M., Marty, M., Lidereau, R., & Bieche, I. (2008). NF-kappa
478 B genes have a major role in inflammatory breast cancer. *BMC Cancer*, 8, 41.

479 Lin, C. M., Singh, S. B., Chu, P. S., Dempcy, R. O., Schmidt, J. M., Pettit, G. R., & Hamel, E. (1988).
480 Interactions of tubulin with potent natural and synthetic analogs of the antimetabolic agent
481 combretastatin: a structure-activity study. *Molecular Pharmacology*, 34, 200-208.

482 Liu, H., Jensen, K. G., Tran, L. M., Chen, M., Zhai, L., Olsen, C. E., Sørhoel, H., Denmeade, S. R., Isaacs,
483 J. T., & Christensen, S. B. (2006). Cytotoxic phenylpropanoids and an additional thapsigargin
484 analogue isolated from *Thapsia garganica*. *Phytochemistry*, 67, 2651-2658.

485 Mueller, M., Hobiger, S., & Jungbauer, A. (2010). Anti-inflammatory activity of extracts from fruits,
486 herbs and spices. *Food Chemistry*, 122, 987-996.

487 Muñoz Acuña, U., Matthew, S., Pan, L., Kinghorn, A. D., Swanson Steven, M., & Carcache de Blanco
488 Esperanza, J. (2013). Apoptosis Induction by 13-Acetoxyrolandrolide through the Mitochondrial
489 Intrinsic Pathway. *Phytotherapy Research*, 28, 1045-1053.

490 Muñoz Acuña, U., Nighat, F., Ahmed, S., Chang, L. C., & Carcache de Blanco, E. J. (2013). Apoptotic
491 effect of wortmannolone on cancer cells through potent ROS induction. *International Journal of*
492 *Cancer Research*, 47(2), 1185-1195.

493 Muñoz-Gámez, J. A., Martín-Oliva, D., Aguilar-Quesada, R., Cañuelo, A., Nuñez, M. I., Valenzuela, M.
494 T., Ruiz de Almodóvar, J. M., De Murcia, G., & Oliver, F. J. (2005). PARP inhibition sensitizes
495 p53-deficient breast cancer cells to doxorubicin-induced apoptosis. *Biochemical Journal*, 386,
496 119-125.

497 Nandan, M. O., McConnell, B. B., Ghaleb, A. M., Bialkowska, A. B., Sheng, H., Shao, J., Babbin, B. A.,
498 Robine, S., & Yang, V. W. (2008). Kruppel-like factor 5 mediates cellular transformation during
499 oncogenic KRAS-induced intestinal tumorigenesis. *Gastroenterology*, 134, 120-130.

500 Perkins, N. D. (2007). Integrating cell-signalling pathways with NF-kappaB and IKK function. *Nature*
501 *Reviews Molecular Cell Biology*, 8, 49-62.

502 Ren, Y., Muñoz Acuña, U. M., Jimenez, F., Garcia, R., Mejia, M., Chai, H., Gallucci, J. C., Farnsworth,
503 N. R., Soejarto, D. D., Carcache de Blanco, E. J., & Kinghorn, A. D. (2012). Cytotoxic and NF-
504 kappaB inhibitory sesquiterpene lactones from *Piptocoma rufescens*. *Tetrahedron*, 68, 2671-
505 2678.

506 Scalbert, A., Manach, C., Morand, C., Rémésy, C., & Jiménez, L. (2005). Dietary polyphenols and the
507 prevention of diseases. *Critical Reviews of Food Science and Nutrition*, 45, 287-306.

508 Singh, S., & Aggarwal, B. B. (1995). Activation of transcription factor NF-kappa B is suppressed by
509 curcumin (diferuloylmethane) [corrected]. *Journal Biological Chemistry*, 270, 24995-25000.

510 Su, B. N., Park, E. J., Mbwambo, Z. H., Santarsiero, B. D., Mesecar, A. D., Fong, H. H., Pezzuto, J. M.,
511 & Kinghorn, A. D. (2002). New chemical constituents of *Euphorbia quinquecostata* and absolute
512 configuration assignment by a convenient Mosher ester procedure carried out in NMR tubes.
513 *Journal of Natural Products*, 65, 1278-1282.

514 Sun, C. L., Yuan, J. M., Koh, W. P., & Yu, M. C. (2006). Green tea, black tea and colorectal cancer risk:
515 a meta-analysis of epidemiologic studies. *Carcinogenesis*, 27, 1301-1309.

516 Surveswaran, S., Cai, Y.-Z., Corke, H., & Sun, M. (2007). Systematic evaluation of natural phenolic
517 antioxidants from 133 Indian medicinal plants. *Food Chemistry*, 102, 938-953.

518 Tang, N. P., Zhou, B., Wang, B., Yu, R. B., & Ma, J. (2009). Flavonoids intake and risk of lung cancer: a
519 meta-analysis. *Japanese Journal of Clinical Oncology*, 39(6), 352-359.

520 Telang, S., Lane, A. N., Nelson, K. K., Arumugam, S., & Chesney, J. (2007). The oncoprotein H-RasV12
521 increases mitochondrial metabolism. *Molecular Cancer*, 6, 77.

522 Van Gils, C., & Cox, P. A. (1994). Ethnobotany of nutmeg in the Spice Islands. *Journal of*
523 *Ethnopharmacology*, 42, 117-124.

524 Wenkert, E., Gottlieb, H. E., Gottlieb, O. R., Pereira, M. O. d. S., & Formiga, M. D. (1976). Carbon-13
525 nuclear magnetic spectroscopy of naturally occurring substances. Part 44. Carbon-13 NMR
526 spectroscopy of neolignans. *Phytochemistry*, 15, 1547-1551.

527 Yan, L., & Spitznagel, E. L. (2009). Soy consumption and prostate cancer risk in men: a revisit of a meta-
528 analysis. *American Journal of Clinical Nutrition*, 89, 1155-1163.

529 Yin, Y., Chen, X., & Shu, Y. (2009). Gene expression of the invasive phenotype of TNF-alpha-treated
530 MCF-7 cells. *Biomed Pharmacother*, 63, 421-428.

531 Zacchino, S. A., & Badano, H. (1991). Enantioselective synthesis and absolute configuration assignment
532 of erythro-(3,4-methylenedioxy-7-hydroxy-1'-allyl-3',5'-dimethoxy)-8.0.4'-neolignan and its
533 acetate, isolated from nutmeg (*Myristica fragrans*). *Journal of Natural Products*, 54, 155-160.

534 Zamora-Ros, R., Forouhi, N. G., Sharp, S. J., González, C. A., Buijsse, B., Guevara, M., van der Schouw,
535 Y. T., Amiano, P., Boeing, H., Bredsdorff, L., Fagherazzi, G., Feskens, E. J., Franks, P. W.,
536 Grioni, S., Katzke, V., Key, T. J., Khaw, K. T., Kühn, T., Masala, G., Mattiello, A., Molina-
537 Montes, E., Nilsson, P. M., Overvad, K., Perquier, F., Redondo, M. L., Ricceri, F., Rolandsson,
538 O., Romieu, I., Roswall, N., Scalbert, A., Schulze, M., Slimani, N., Spijkerman, A. M.,
539 Tjønneland, A., Tormo, M. J., Touillaud, M., Tumino, R., van der A, D. L., van Woudenberg, G.
540 J., Langenberg, C., Riboli, E., & Wareham, N. J. (2014). Dietary intakes of individual flavanols

541 and flavonols are inversely associated with incident type 2 diabetes in European populations.
542 *Journal of Nutrition*, 144, 335-343.

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

Fig 1. Chemical structures of compounds (**1-5**) from the ethyl acetate extract of *M. fragrans*

Fig 2. The structure of the novel compound (*S*) 1-(3, 4, 5-trimethoxy phenyl)- 2-(3-methoxy-5-

(prop -1-yl) phenyl)- propan-1-ol (**1**).

Fig 3. Results obtained from Mosher ester reaction. Illustration of difference in chemical shift δ -values ($\Delta\delta^{S-R}$) of (**1**) (*S*) 1-(3, 4, 5-trimethoxy phenyl)-2-(3-methoxy-5-(prop -1-yl) phenyl)-propan-1-ol.

Table 1

NMR spectral data of ^1H and ^{13}C for (**1**) (*S*) 1-(3, 4, 5-trimethoxy phenyl)-2-(3-methoxy-5-(prop -1-yl) phenyl)-propan-1-ol (in 400 MHz, chloroform- d_6)

Table 2

Cytotoxic activity, K-Ras, PARP-1, and NF- κ B inhibition of secondary metabolites from mace (**1- 5**).

574

575

576

577

578

579

Fig 1. Chemical structures of compounds (1-5) from the ethyl acetate extract of *M. fragrans*.

580

581

582

583

Fig 2. The structure of the novel compound (*S*) 1-(3, 4, 5-trimethoxy phenyl)-2-(3-methoxy-5-(prop -1-yl) phenyl)-propan-1-ol (**1**).

584

585

Fig 3. Results obtained from Mosher ester reaction. Illustration of difference in chemical shift δ -values ($\Delta\delta^{S-R}$) of (**1**) (*S*) 1-(3, 4, 5-trimethoxy phenyl)-2-(3-methoxy-5-(prop -1-yl) phenyl)-propan-1-ol.

Table 1

NMR spectral data of ^1H and ^{13}C for **(1)** (*S*) 1-(3, 4, 5-trimethoxy phenyl) - 2-(3-methoxy-5-(prop -1-yl) phenyl)-propan-1-ol (in 400 MHz, chloroform- d_6)

Position	Compound 1 (CDCl_3)	
	δ_{C}	δ_{H} (J in Hz)
1	94.4	5.10 (d, $J = 9.6$)
2	46.2	3.50 (s)
3	18.2	1.41 (d, $J = 6.7$)
1'	133.7	
2'	113.8	6.77 (s)
3'	131.4	
4'	114.6	6.82
5'	144.6	
6'	106.1	6.46(s)
1''	132.6	
2''	109.3	6.98 (s)
3''	146.3	
4''	150.9	
5''	146.3	
6''	109.3	6.98(s)
α	131.4	6.40 (dd, $J = 1.9, 16$)
β	123.6	6.10 (dd, $J = 6.5, 16$)
γ	19.0	1.89 (d $J = 1.9, 6.5$)
O-Me	56.4	3.90 (s)

Table 2Cytotoxic activity, K-Ras, PARP-1, and NF-κB inhibition of secondary metabolites from mace (**1- 5**).

Compound	NF-κB (HeLa) ^a	K-Ras (HT-29)	PARP-1	Cytotoxicity (HT-29) ^b
	IC ₅₀ (μM)	IC ₅₀ (μM)	IC ₅₀ (μM)	IC ₅₀ (μM)
1	Not active	10.5	3.04	-
2	0.0015	Not active	0.001	3.07
3	62	Not tested	Not tested	Not tested
4	0.0034	Not active	22.07	0.024
5	Not active	Not active	3.11	0.003

^a Data presented as IC₅₀ values with rocaglamide used as the positive control (IC₅₀= 0.075 ± μM). ^b Data presented as IC₅₀ values with paclitaxel used as the positive control (IC₅₀= 0.5 ± 0.6nM)